A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 Dec 2019 to 10 Jan 2020.
    • 30 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 02 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top